Skip to main content

KB-0742 dihydrochloride (C09-1141-436)

Aladdin

Catalog No.
C09-1141-436
Manufacturer No.
K649087-50mg
Manufacturer Name
Aladdin Scientific
Quantity
1
Unit of Measure
EA
Price: $1,766.42
List Price: $1,962.69

KB-0742 dihydrochloride is a potent, selective and orally active CDK9 inhibitor with an IC 50 of 6 nM for CDK9/cyclin T1 . KB-0742 dihydrochloride is selective for CDK9/cyclin T1 with >:50-fold selectivity over other CDK kinases. KB-0742

Enjoy exclusive benefits including discounted pricing on orders by contacting our Sales Executives to open an account.

Adding to cart… The item has been added
KB-0742 dihydrochloride is a potent, selective and orally active CDK9 inhibitor with an IC 50 of 6 nM for CDK9/cyclin T1 . KB-0742 dihydrochloride is selective for CDK9/cyclin T1 with >50-fold selectivity over other CDK kinases. KB-0742 dihydrochloride has potent anti-tumor activityIn VitroKB-0742 (6 hours; 0.1-10 μM; 22Rv1 cells) treatment significant reduction of downstream phosphorylation of RNA Pol II at Ser2 and Ser7, and diminished phosphorylation at Ser5. Global androgen receptor (AR)-FL and AR-V protein levels are significantly reduced starting at 6 h treatment time, which is accompanied by the reduction of phospho-AR levels (Ser81). KB-0742 (48-72 hours) treatment shows cytostatic effects in prostate cancer and leukemia cell lines. KB-0742 shows antiproliferative activity with GR 50 s of 0.183 μM and 0.288 μM for 22Rv1 cells and MV-4-11 AML cells, respectively. In 22Rv1 cells, KB-0742 rapidly downregulates nascent transcription, preferentially depleting short half-life transcripts and AR-driven oncogenic programs. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCell Line: 22Rv1 cells Concentration: 0.1 μM, 0.5 μM, 1 μM, 10 μM Incubation Time: 6 hours Result: Significant reduction of downstream phosphorylation of RNA Pol II at Ser2 and Ser7, and diminished phosphorylation at Ser5.In VivoKB-0742 (3-30 mg/kg; p.o.; daily; over 21 days) is well tolerated even at high dose, while significantly reducing tumor burden in 22Rv1 human prostate cancer cell line-derived xenograft (CDX) models . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male CB17-SCID mice injected with 22Rv1 human prostate cancer cells Dosage: 3 mg/kg, 10 mg/kg, and 30 mg/kg Administration: p.o.; daily; over 21 days Result: Significantly reduced tumor growth in castration-resistant prostate cancer (CRPC).Form:SolidIC50& Target:CDK9/cyclinT1 6 nM (IC 50 ). Specification: 0.99 Molecular Formula: C16H27Cl2N5 Molecular Weight: 360.33 PubChem CID: 155819527
UPC:
12352107
Condition:
New
Availability:
8-12 weeks
Weight:
1.06 Ounces
HazmatClass:
No
WeightUOM:
LB
MPN:
K649087-50mg
CAS:
2416874-75-2
Product Size:
50mg


Cenmed Satisfaction Guarantee

At Cenmed, your confidence and satisfaction are paramount. We guarantee the quality and reliability of our extensive range of clinical and laboratory supplies. If you're not completely satisfied with your purchase, we offer a straightforward return process and dedicated support to resolve your concerns promptly. Our commitment ensures that you can order with confidence, knowing that Cenmed is dedicated to superior service and customer satisfaction. Trust us to meet your needs with every order, backed by our promise of excellence. Learn more in Help & FAQs.


"Cenmed provides me access to the same products/services normally reserved for much larger labs than mine. I was presently surprised by their product offering."

LAB DIRECTOR


"We utilized Cenmed's capabilities for a variety of projects around the world. They are a valued partner and supplier."

PHARMACEUTICAL SUPPLY CHAIN LEADER


"The reps are very good at finding products for customers in this period of supply chain issues."

SCOTT BEHMAN


"Your customer service has been excellent and makes me excited about purchasing with Cenmed in the future!!"

PROCUREMENT + BILLING COORDINATOR AT PHARMA.